Buscar
Zymeworks Inc
ZYMEAñadir a la lista de seguimiento
25.720USD
-0.420-1.61%
Cierre 07/01, 16:00（ET）Cotizaciones retrasadas 15 min
1.84BCap. mercado
PérdidaP/E TTM
Más Datos de Zymeworks Inc Compañía
Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.
Información de Zymeworks Inc
Símbolo de cotizaciónZYME
Nombre de la empresaZymeworks Inc
Fecha de salida a bolsaJun 24, 2019
Director ejecutivoGalbraith (Kenneth H)
Número de empleados280
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 24
Dirección108 Patriot Drive, Suite A
CiudadMIDDLETOWN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal19709
Teléfono13022748744
Sitio Webhttps://www.zymeworks.com/
Símbolo de cotizaciónZYME
Fecha de salida a bolsaJun 24, 2019
Director ejecutivoGalbraith (Kenneth H)
Ejecutivos de Zymeworks Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Kenneth H. (Ken) Galbraith
Mr. Kenneth H. (Ken) Galbraith
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Susan M. (Sue) Mahony, Ph.D.
Dr. Susan M. (Sue) Mahony, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Kelvin M. Neu ,M.D.
Dr. Kelvin M. Neu ,M.D.
Independent Director
Independent Director
--
--
Dr. Paul A. Moore, Ph.D.
Dr. Paul A. Moore, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Carlos E. Campoy
Mr. Carlos E. Campoy
Independent Director
Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Scott Platshon
Mr. Scott Platshon
Acting Chief Investment Officer
Acting Chief Investment Officer
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Chief Financial Officer, Chief Business Officer, Executive Vice President
Chief Financial Officer, Chief Business Officer, Executive Vice President
--
--
Dr. Jeffrey Smith, M.D.
Dr. Jeffrey Smith, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Mr. Oleg Nodelman
Mr. Oleg Nodelman
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Kenneth H. (Ken) Galbraith
Mr. Kenneth H. (Ken) Galbraith
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Susan M. (Sue) Mahony, Ph.D.
Dr. Susan M. (Sue) Mahony, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Kelvin M. Neu ,M.D.
Dr. Kelvin M. Neu ,M.D.
Independent Director
Independent Director
--
--
Dr. Paul A. Moore, Ph.D.
Dr. Paul A. Moore, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Carlos E. Campoy
Mr. Carlos E. Campoy
Independent Director
Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Zymeworks Inc?
Los cinco principales accionistas de Zymeworks Inc son: Mr. Kenneth H. (Ken) Galbraith